MedTrace Logo

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

NCT04596150 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2024-01-23

No results posted yet for this study

Summary

A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC

Conditions

  • Neoplasms
  • Breast Neoplasms
  • Breast Neoplasms, Triple-Negative
  • Breast Cancer
  • Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

Interventions

DRUG

CX-2009

Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)

DRUG

CX-072

Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)

Sponsors & Collaborators

  • CytomX Therapeutics

    lead INDUSTRY

Principal Investigators

  • Monika Vainorius, M.D. · CytomX Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-29
Primary Completion
2023-06-02
Completion
2023-06-02
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04596150 on ClinicalTrials.gov